Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2009

01.06.2009

Advantages and disadvantages of GH/IGF-I combination treatment

verfasst von: J. A. M. J. L. Janssen

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Growth hormone (GH) is the primary regulator of insulin-like growth factor-I (IGF-I) production in a wide variety of tissues. There is much overlap in the endocrine, metabolic and anabolic effects of GH and IGF-I but both hormones have divergent effects on glucose metabolism, insulin sensitivity and differentiation of prechondrocytes. Theoretically combined administration of GH and IGF-I may be more effective than GH alone or IGF-I alone. Arguments in favor for this are: 1] Clearance of IGF-I may be markedly altered by the co-administration of GH and this will provide sustained actions of IGF-I. 2] Higher serum IGF-I levels are achieved with a combination treatment of GH and IGF-I than with GH treatment alone or IGF-I alone. In addition, combination therapy may have additive or synergistic effects. 3] The combination GH and IGF-I counteracts disadvantageous effects on glucose metabolism of either GH alone or IGF-I alone. 4] GH may exert direct actions on tissues independently from IGF-I. 5] Combination of GH and IGF-I may be more effective in improving tissue IGF-I levels. The combination therapy of GH and IGF-I might be beneficial in growth retardation, in certain specific subgroups of critically ill or catabolic patients and in the treatment of GH-deficient subjects with the metabolic syndrome and/or manifest diabetes. It is at present unknown whether an optimal balance between safety and efficacy can be achieved with the combination therapy of GH and IGF-I, since this combination has been evaluated in only a small number of patient populations and in studies of a relatively short duration. In addition, a disadvantage may be the financial costs of combination therapy of GH and IGF-I. In conclusion, there are many reasons for believing that administration of the combination therapy of GH and IGF-I could have advantages above GH alone or IGF-I alone. However, determination of whether co-administration of GH and IGF-I indeed is superior to either agent alone awaits further study.
Literatur
1.
Zurück zum Zitat Blum WF. Chapter 3: Insulin-like growth factors and IGF-binding proteins: their use for diagnosis of growth hormone deficiency. In: Juul A, Jorgensen JOL, editors. Growth hormone in adults. Cambridge: Cambridge University Press; 1996. p. 48–74. Blum WF. Chapter 3: Insulin-like growth factors and IGF-binding proteins: their use for diagnosis of growth hormone deficiency. In: Juul A, Jorgensen JOL, editors. Growth hormone in adults. Cambridge: Cambridge University Press; 1996. p. 48–74.
4.
Zurück zum Zitat Hussain MA, Schmitz O, Froesch ER. Growth hormone, insulin, and insulin-like growth factor I: revisiting the food and famine theory. News Physiol Sci 1995;10:81–6. Hussain MA, Schmitz O, Froesch ER. Growth hormone, insulin, and insulin-like growth factor I: revisiting the food and famine theory. News Physiol Sci 1995;10:81–6.
5.
Zurück zum Zitat Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994;120:593–601.PubMed Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994;120:593–601.PubMed
10.
Zurück zum Zitat Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994;42:140–4.PubMedCrossRef Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994;42:140–4.PubMedCrossRef
15.
Zurück zum Zitat Jenkins RC, Ross RJ. Growth hormone therapy for protein catabolism. Q J Med 1996;89:813–9. Jenkins RC, Ross RJ. Growth hormone therapy for protein catabolism. Q J Med 1996;89:813–9.
17.
Zurück zum Zitat Botfield C, Hinds CJ. Growth hormone and IGF-I as anabolic therapy. In: Jenkins RC, Ross RJM, editors. The endocrine response to acute illness. Front Horm Res. vol 24. Basel: Karger; 1999. p. 176–200.CrossRef Botfield C, Hinds CJ. Growth hormone and IGF-I as anabolic therapy. In: Jenkins RC, Ross RJM, editors. The endocrine response to acute illness. Front Horm Res. vol 24. Basel: Karger; 1999. p. 176–200.CrossRef
18.
Zurück zum Zitat Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993;91:391–6. doi:10.1172/JCI116212.PubMedCrossRef Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993;91:391–6. doi:10.​1172/​JCI116212.PubMedCrossRef
20.
Zurück zum Zitat Rosenbloom AL, Connor EL. Chapter 3: Hypopituitarism and other disorders of the growth hormone-insulin-like growth factor-I axis. In: Lifshitz F, editor. Pediatric endocrinology. 5th ed. New York: Informa Healthcare; 2007. p. 65–99. Rosenbloom AL, Connor EL. Chapter 3: Hypopituitarism and other disorders of the growth hormone-insulin-like growth factor-I axis. In: Lifshitz F, editor. Pediatric endocrinology. 5th ed. New York: Informa Healthcare; 2007. p. 65–99.
21.
Zurück zum Zitat Grahnén A, Kastrup K, Heinrich U, Gourmelen M, Preece MA, Vaccarello MA, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl 1993;82(Suppl 391):9–13. doi:10.1111/j.1651-2227.1993.tb12918.x.PubMedCrossRef Grahnén A, Kastrup K, Heinrich U, Gourmelen M, Preece MA, Vaccarello MA, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl 1993;82(Suppl 391):9–13. doi:10.​1111/​j.​1651-2227.​1993.​tb12918.​x.PubMedCrossRef
22.
Zurück zum Zitat Rosenbloom AL. IGF-I treatment of growth hormone sensitivity. In: Rosenfeld RG, Roberts CT, editors. The IGF system: molecular biology, physiology, and clinical applications. Towata, New Jersey: Humana; 1999. p. 739–69. Rosenbloom AL. IGF-I treatment of growth hormone sensitivity. In: Rosenfeld RG, Roberts CT, editors. The IGF system: molecular biology, physiology, and clinical applications. Towata, New Jersey: Humana; 1999. p. 739–69.
23.
Zurück zum Zitat Hatton J, Kryscio R, Ryan M, Ott L, Young B. Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. J Neurosurg 2006;105:843–52. doi:10.3171/jns.2006.105.6.843.PubMedCrossRef Hatton J, Kryscio R, Ryan M, Ott L, Young B. Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. J Neurosurg 2006;105:843–52. doi:10.​3171/​jns.​2006.​105.​6.​843.PubMedCrossRef
25.
26.
27.
Zurück zum Zitat Nguyen BY, Clerici M, Venzon DJ, Bauza S, Murphy WJ, Longo DL, et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 1998;12:895–904. doi:10.1097/00002030-199808000-00012.PubMedCrossRef Nguyen BY, Clerici M, Venzon DJ, Bauza S, Murphy WJ, Longo DL, et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 1998;12:895–904. doi:10.​1097/​00002030-199808000-00012.PubMedCrossRef
28.
Zurück zum Zitat Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989;10:68–91.PubMedCrossRef Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989;10:68–91.PubMedCrossRef
29.
Zurück zum Zitat Sandra A, Boes M, Dake BL, Stokes JB, Bar RS. Infused IGF-I/IGFBP-3 complex causes glomerular localization of IGF-I in the rat kidney. Am J Physiol 1998;275:E32–7.PubMed Sandra A, Boes M, Dake BL, Stokes JB, Bar RS. Infused IGF-I/IGFBP-3 complex causes glomerular localization of IGF-I in the rat kidney. Am J Physiol 1998;275:E32–7.PubMed
30.
Zurück zum Zitat Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800–9.PubMed Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800–9.PubMed
33.
Zurück zum Zitat Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–5. doi:10.1093/jnci/91.7.620.PubMedCrossRef Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–5. doi:10.​1093/​jnci/​91.​7.​620.PubMedCrossRef
35.
Zurück zum Zitat Lee PD, Pivarnik JM, Bukar JG, Muurahainen N, Berry PS, Skolnik PR, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996;81:2968–75. doi:10.1210/jc.81.8.2968.PubMedCrossRef Lee PD, Pivarnik JM, Bukar JG, Muurahainen N, Berry PS, Skolnik PR, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996;81:2968–75. doi:10.​1210/​jc.​81.​8.​2968.PubMedCrossRef
36.
Zurück zum Zitat Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994;94:1126–33. doi:10.1172/JCI117427.PubMedCrossRef Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994;94:1126–33. doi:10.​1172/​JCI117427.PubMedCrossRef
Metadaten
Titel
Advantages and disadvantages of GH/IGF-I combination treatment
verfasst von
J. A. M. J. L. Janssen
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2009
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-008-9081-5

Weitere Artikel der Ausgabe 2/2009

Reviews in Endocrine and Metabolic Disorders 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.